» Articles » PMID: 7890302

Soluble TNF Receptor Production by Activated T Lymphocytes: Differential Effects of Acute and Chronic Exposure to TNF

Overview
Journal Immunology
Date 1995 Jan 1
PMID 7890302
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Soluble tumour necrosis factor receptors (sTNF-R) are up-regulated at sites of chronic inflammation such as rheumatoid synovial joints. The p75 sTNF-R is the more abundant, suggesting an important role for this TNF inhibitor in regulating TNF bioactivity in vivo. As the precise cellular source of these soluble receptors is not known, we investigated the production and regulation of sTNF-R by T lymphocytes, an abundant cell type in inflammatory infiltrates, which upon activation express high levels of p75 surface receptors. Using panels of T-cell lines and clones expressing high levels of p75 TNF-R, we found that p75 sTNF-R production upon stimulation is a feature common to all subsets of T cells, including cells of the CD4-CD8- double negative phenotype expressing either alpha beta or gamma delta T-cell receptors (TCR). In contrast, levels of p55 sTNF-R were only detected when T cells were stimulated at higher densities and by potent mitogens such as phorbol 12-myristate 13-acetate (PMA). Detailed kinetic analyses revealed that the production of p75 sTNF-R was biphasic, the first phase was activation dependent, occurring in the absence of detectable TNF, while the second phase of p75 sTNF-R production was regulated by cytokines such as TNF. Unlike short-term exposure to TNF which enhances sTNF-R production in vitro and in vivo, prolonged exposure of T lymphocytes to TNF suppressed p75 sTNF-R (but not p55 sTNF-R) production in a dose- and time-dependent fashion. These results suggest that in patients with chronic inflammatory disease, which are exposed to augmented levels of bioactive TNF for prolonged periods, the production of p75 sTNF-R may be impaired.

Citing Articles

O-glycosylation and its role in therapeutic proteins.

Thompson N, Wakarchuk W Biosci Rep. 2022; 42(10).

PMID: 36214107 PMC: 9620488. DOI: 10.1042/BSR20220094.


Treelet transform analysis to identify clusters of systemic inflammatory variance in a population with moderate-to-severe traumatic brain injury.

Vijapur S, Vaughan L, Awan N, DiSanto D, McKernan G, Wagner A Brain Behav Immun. 2021; 95:45-60.

PMID: 33524553 PMC: 9004489. DOI: 10.1016/j.bbi.2021.01.026.


Anti-Pituitary and Anti-Hypothalamus Autoantibody Associations with Inflammation and Persistent Hypogonadotropic Hypogonadism in Men with Traumatic Brain Injury.

Vijapur S, Yang Z, Barton D, Vaughan L, Awan N, Kumar R J Neurotrauma. 2020; 37(14):1609-1626.

PMID: 32111134 PMC: 7336882. DOI: 10.1089/neu.2019.6780.


Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis.

Romeo B, Brunet-Lecomte M, Martelli C, Benyamina A Int J Neuropsychopharmacol. 2018; 21(9):828-836.

PMID: 30016466 PMC: 6119290. DOI: 10.1093/ijnp/pyy062.


Shedding of TNF receptor 2 by effector CD8⁺ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection.

DeBerge M, Ely K, Wright P, Thorp E, Enelow R J Leukoc Biol. 2015; 98(3):423-34.

PMID: 26019295 PMC: 4763598. DOI: 10.1189/jlb.3A0914-432RR.


References
1.
Lantz M, Malik S, Slevin M, Olsson I . Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 1990; 2(6):402-6. DOI: 10.1016/1043-4666(90)90048-x. View

2.
Collart M, Belin D, Vassalli J, de Kossodo S, Vassalli P . Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med. 1986; 164(6):2113-8. PMC: 2188497. DOI: 10.1084/jem.164.6.2113. View

3.
Cope A, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones A . Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992; 35(10):1160-9. DOI: 10.1002/art.1780351008. View

4.
Santis A, Campanero M, Alonso J, Sanchez-Madrid F . Regulation of tumor necrosis factor (TNF)-alpha synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway. Eur J Immunol. 1992; 22(12):3155-60. DOI: 10.1002/eji.1830221219. View

5.
Mackay F, Loetscher H, Stueber D, Gehr G, LESSLAUER W . Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 1993; 177(5):1277-86. PMC: 2190994. DOI: 10.1084/jem.177.5.1277. View